Yahoo · Aug 11, 2026
The Zacks Analyst Blog Highlights Illumina, Qnity Electronics and nVent Electric
Illumina, Qnity Electronics and nVent Electric lead Zacks' latest Strong Buy picks as markets eye inflation, rates and global risks.
IL
NASDAQ · ILMN
Illumina, Inc.
Healthcare · Medical - Diagnostics & Research
$188.29
Up+$15.11 (+8.02%)
Updated Aug 19, 2026, 5:31 PM
SID Score
6.4/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 20.84B
- P/E ratio
- 30.27
- Dividend yield
- 0.00%
- 52-week range
- $88.00 – $207.00
- Volume
- 1.19M
- Avg. volume
- 1.79M
Price performance
ILMN price history
1M range · 21 trading sessions · Daily adjusted prices
ILMN closed at $188.29 after 21 trading sessions, down 2.20% for the selected period.
- Last close
- $188.29
- Period change
- -2.20%
- Period low
- $187.96
- Period high
- $205.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $192.13 | $192.83 | $187.541 | $188.29 | 1.19M |
| Aug 17, 2026 | $191.01 | $193.85 | $188.94 | $193.135 | 995.96K |
| Aug 14, 2026 | $190.05 | $192.775 | $188.0002 | $190.89 | 993.08K |
| Aug 13, 2026 | $194.00 | $194.50 | $187.44 | $192.64 | 1.06M |
| Aug 12, 2026 | $192.01 | $193.5515 | $189.24 | $192.91 | 1.26M |
| Aug 11, 2026 | $191.68 | $193.12 | $187.625 | $192.84 | 867.97K |
| Aug 10, 2026 | $186.69 | $193.45 | $186.64 | $191.79 | 1.69M |
| Aug 7, 2026 | $195.67 | $196.04 | $187.46 | $187.96 | 1.83M |
| Aug 6, 2026 | $196.73 | $196.73 | $187.05 | $193.72 | 4.28M |
| Aug 5, 2026 | $203.50 | $203.75 | $197.0824 | $199.87 | 2.27M |
| Aug 4, 2026 | $199.264 | $203.44 | $196.0001 | $203.01 | 3.1M |
| Aug 3, 2026 | $204.14 | $207.00 | $197.93 | $198.16 | 2.61M |
| Jul 31, 2026 | $203.28 | $205.93 | $192.6844 | $205.10 | 4.1M |
| Jul 30, 2026 | $196.00 | $205.47 | $194.49 | $205.09 | 2.77M |
| Jul 29, 2026 | $193.24 | $196.68 | $189.4705 | $194.82 | 1.69M |
| Jul 28, 2026 | $190.66 | $194.99 | $187.67 | $192.98 | 2.11M |
| Jul 27, 2026 | $194.35 | $195.04 | $188.51 | $189.47 | 1.74M |
| Jul 24, 2026 | $198.00 | $198.00 | $191.57 | $194.09 | 1.3M |
| Jul 23, 2026 | $193.02 | $199.1395 | $192.82 | $196.86 | 1.22M |
| Jul 22, 2026 | $190.00 | $194.65 | $188.00 | $190.87 | 1.55M |
| Jul 21, 2026 | $180.03 | $192.88 | $178.88 | $192.53 | 1.37M |
Latest ILMN news
The latest Smart Investors Daily articles mentioning ILMN.
Stock researchCompany · Overview
ILMN research
Overview
Company profile and research snapshot.
Company profile
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $115.25
- Implied upside
- —
- Analysts
- 28
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Canaccord Genuity | Hold | — |
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Aug 3, 2026 | Citigroup | Sell | — |
| Jul 31, 2026 | Guggenheim | Buy | — |
| Jul 31, 2026 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 7, 2026
What Makes Illumina (ILMN) a New Strong Buy Stock
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Aug 5, 2026
Standard BioTools Reports Second Quarter 2026 Financial Results
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.1 million1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-yearMerger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026 “We remain on track to close our merger
Benzinga · Aug 5, 2026
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 3.84% on an annualized basis producing an average annual return of 13.26%. Currently, Illumina has a market capitalization of $30.65 billion.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
